Search
Patupilone
go.drugbank.com/drugs/DB03010InvestigationalEpothilone B is a 16-membered macrolide that mimics the biological effects of taxol.
AT1391
go.drugbank.com/drugs/DB05120ExperimentalAT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.
Otenabant
go.drugbank.com/drugs/DB11745InvestigationalOtenabant has been investigated for the treatment of Obesity.
Categories: Cannabinoid Receptor Antagonists, Receptor, Cannabinoid, CB1, antagonists & inhibitorsEprodisate
go.drugbank.com/drugs/DB06405InvestigationalEprodisate slows the decline of renal function in AA amyloidosis.
Sofalcone
go.drugbank.com/drugs/DB05197ExperimentalSofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion
Rolofylline
go.drugbank.com/drugs/DB12670InvestigationalRolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.
GC-376 free acid
go.drugbank.com/drugs/DB15796ExperimentalThe compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056]. … A prodrug of [GC-373], GC-376 has recently been used to test inhibition of SARS-Cov-2 M<sup>pro</sup> _in vitro_, and results show potent inhibition of this target[A219036].
GlycoPEG-GCSF
go.drugbank.com/drugs/DB06022ExperimentalGlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
Laromustine
go.drugbank.com/drugs/DB05817InvestigationalVNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
SC12267
go.drugbank.com/drugs/DB05125InvestigationalSC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.